{"entity":{"type":"insider","cik":"0001788608","url":"/insider/0001788608","json_url":"/insider/0001788608.json","name":"Levy Noah G.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":66,"n_filings":24,"first":"2020-04-07","last":"2023-01-17","span_basis":"filed_date"},"name_variants":[{"name":"Levy Noah G.","source":"filing","n_filings":24,"first_seen":"2020-04-07","last_seen":"2023-01-17"}],"transactions":[{"id":8010001,"accession":"0000899243-23-001838","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-001838","line_url":"/filing/0000899243-23-001838#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; Newtyn Capital Partners, LP; Newtyn Management, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":11.9,"price_display":"11.90","price_state":"stated","total_value":1190000.0,"total_display":"1,190,000.00","total_whole":"1,190,000","shares_owned_after":1119586.0,"shares_owned_after_display":"1,119,586","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-12","filed_date":"2023-01-17","scope":"insider"},{"id":7854532,"accession":"0000899243-23-000580","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-000580","line_url":"/filing/0000899243-23-000580#line-2","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; Ledo Capital, LLC; Newtyn Capital Partners, LP; Newtyn Management, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5300.0,"shares_display":"5,300","price_per_share":11.2384,"price_display":"11.24","price_state":"stated","total_value":59563.52,"total_display":"59,563.52","total_whole":"59,564","shares_owned_after":1019586.0,"shares_owned_after_display":"1,019,586","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-03","filed_date":"2023-01-04","scope":"insider"},{"id":7854528,"accession":"0000899243-23-000580","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-000580","line_url":"/filing/0000899243-23-000580#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; Ledo Capital, LLC; Newtyn Capital Partners, LP; Newtyn Management, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1300.0,"shares_display":"1,300","price_per_share":11.2423,"price_display":"11.24","price_state":"stated","total_value":14614.99,"total_display":"14,614.99","total_whole":"14,615","shares_owned_after":1014286.0,"shares_owned_after_display":"1,014,286","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-30","filed_date":"2023-01-04","scope":"insider"},{"id":6443685,"accession":"0000899243-22-026124","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-026124","line_url":"/filing/0000899243-22-026124#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.; Newtyn Capital Partners, LP; Ledo Capital, LLC","owner_display_name":"NEWTYN PARTNERS, LP","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3095.0,"shares_display":"3,095","price_per_share":5.8891,"price_display":"5.89","price_state":"stated","total_value":18226.7645,"total_display":"18,226.76","total_whole":"18,227","shares_owned_after":754108.0,"shares_owned_after_display":"754,108","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-13","filed_date":"2022-07-15","scope":"insider"},{"id":6588627,"accession":"0000899243-22-026020","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-026020","line_url":"/filing/0000899243-22-026020#line-2","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC; NEWTYN PARTNERS, LP; Levy Noah G.","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2816.0,"shares_display":"2,816","price_per_share":5.8649,"price_display":"5.86","price_state":"stated","total_value":16515.5584,"total_display":"16,515.56","total_whole":"16,516","shares_owned_after":751013.0,"shares_owned_after_display":"751,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-12","filed_date":"2022-07-13","scope":"insider"},{"id":6588622,"accession":"0000899243-22-026020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-026020","line_url":"/filing/0000899243-22-026020#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC; NEWTYN PARTNERS, LP; Levy Noah G.","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700.0,"shares_display":"700","price_per_share":5.9737,"price_display":"5.97","price_state":"stated","total_value":4181.59,"total_display":"4,181.59","total_whole":"4,182","shares_owned_after":748197.0,"shares_owned_after_display":"748,197","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-11","filed_date":"2022-07-13","scope":"insider"},{"id":6914632,"accession":"0000899243-22-025909","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-025909","line_url":"/filing/0000899243-22-025909#line-2","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1378.0,"shares_display":"1,378","price_per_share":5.9863,"price_display":"5.99","price_state":"stated","total_value":8249.1214,"total_display":"8,249.12","total_whole":"8,249","shares_owned_after":747497.0,"shares_owned_after_display":"747,497","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-08","filed_date":"2022-07-11","scope":"insider"},{"id":6914630,"accession":"0000899243-22-025909","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-025909","line_url":"/filing/0000899243-22-025909#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1100.0,"shares_display":"1,100","price_per_share":5.9873,"price_display":"5.99","price_state":"stated","total_value":6586.03,"total_display":"6,586.03","total_whole":"6,586","shares_owned_after":746119.0,"shares_owned_after_display":"746,119","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-07","filed_date":"2022-07-11","scope":"insider"},{"id":6670321,"accession":"0000899243-22-024972","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-024972","line_url":"/filing/0000899243-22-024972#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Levy Noah G.; Ledo Capital, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1550.0,"shares_display":"1,550","price_per_share":5.7558,"price_display":"5.76","price_state":"stated","total_value":8921.49,"total_display":"8,921.49","total_whole":"8,921","shares_owned_after":745019.0,"shares_owned_after_display":"745,019","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-30","filed_date":"2022-07-05","scope":"insider"},{"id":6386224,"accession":"0000899243-22-024187","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-024187","line_url":"/filing/0000899243-22-024187#line-2","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Levy Noah G.; Ledo Capital, LLC; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":5.99,"price_display":"5.99","price_state":"stated","total_value":5990.0,"total_display":"5,990.00","total_whole":"5,990","shares_owned_after":743469.0,"shares_owned_after_display":"743,469","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-24","filed_date":"2022-06-27","scope":"insider"},{"id":6386220,"accession":"0000899243-22-024187","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-024187","line_url":"/filing/0000899243-22-024187#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Levy Noah G.; Ledo Capital, LLC; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":3000.0,"total_display":"3,000.00","total_whole":"3,000","shares_owned_after":742469.0,"shares_owned_after_display":"742,469","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-23","filed_date":"2022-06-27","scope":"insider"},{"id":6944870,"accession":"0000899243-22-023332","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-023332","line_url":"/filing/0000899243-22-023332","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":900.0,"shares_display":"900","price_per_share":5.9692,"price_display":"5.97","price_state":"stated","total_value":5372.28,"total_display":"5,372.28","total_whole":"5,372","shares_owned_after":1012986.0,"shares_owned_after_display":"1,012,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-17","filed_date":"2022-06-21","scope":"insider","n_lines":2},{"id":6944863,"accession":"0000899243-22-023332","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-023332","line_url":"/filing/0000899243-22-023332","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":520.0,"shares_display":"520","price_per_share":5.448,"price_display":"5.45","price_state":"stated","total_value":2832.96,"total_display":"2,832.96","total_whole":"2,833","shares_owned_after":1012471.0,"shares_owned_after_display":"1,012,471","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-16","filed_date":"2022-06-21","scope":"insider","n_lines":2},{"id":6235912,"accession":"0000899243-22-022785","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-022785","line_url":"/filing/0000899243-22-022785","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; NEWTYN PARTNERS, LP; Levy Noah G.; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Ledo Capital, LLC","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2900.0,"shares_display":"2,900","price_per_share":5.3659,"price_display":"5.37","price_state":"stated","total_value":15561.11,"total_display":"15,561.11","total_whole":"15,561","shares_owned_after":1012174.0,"shares_owned_after_display":"1,012,174","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-15","filed_date":"2022-06-16","scope":"insider","n_lines":2},{"id":6235904,"accession":"0000899243-22-022785","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-022785","line_url":"/filing/0000899243-22-022785","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; NEWTYN PARTNERS, LP; Levy Noah G.; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Ledo Capital, LLC","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20938.0,"shares_display":"20,938","price_per_share":5.1733,"price_display":"5.17","price_state":"stated","total_value":108318.5554,"total_display":"108,318.56","total_whole":"108,319","shares_owned_after":1010515.0,"shares_owned_after_display":"1,010,515","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-14","filed_date":"2022-06-16","scope":"insider","n_lines":2},{"id":6471912,"accession":"0000899243-22-022373","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-022373","line_url":"/filing/0000899243-22-022373","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; NEWTYN PARTNERS, LP; Ledo Capital, LLC; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Newtyn Capital Partners, LP","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9699.0,"shares_display":"9,699","price_per_share":5.1488,"price_display":"5.15","price_state":"stated","total_value":49938.2112,"total_display":"49,938.21","total_whole":"49,938","shares_owned_after":998538.0,"shares_owned_after_display":"998,538","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-13","filed_date":"2022-06-14","scope":"insider","n_lines":2},{"id":6471905,"accession":"0000899243-22-022373","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-022373","line_url":"/filing/0000899243-22-022373","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; NEWTYN PARTNERS, LP; Ledo Capital, LLC; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Newtyn Capital Partners, LP","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6386.0,"shares_display":"6,386","price_per_share":4.9206,"price_display":"4.92","price_state":"stated","total_value":31422.9516,"total_display":"31,422.95","total_whole":"31,423","shares_owned_after":992990.0,"shares_owned_after_display":"992,990","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-10","filed_date":"2022-06-14","scope":"insider","n_lines":2},{"id":6944010,"accession":"0000899243-22-003837","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-003837","line_url":"/filing/0000899243-22-003837","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Levy Noah G.; Newtyn Management, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1237.0,"shares_display":"1,237","price_per_share":5.0493,"price_display":"5.05","price_state":"stated","total_value":6245.9841,"total_display":"6,245.98","total_whole":"6,246","shares_owned_after":989337.0,"shares_owned_after_display":"989,337","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-01","scope":"insider","n_lines":2},{"id":6944005,"accession":"0000899243-22-003837","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-003837","line_url":"/filing/0000899243-22-003837","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Levy Noah G.; Newtyn Management, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12963.0,"shares_display":"12,963","price_per_share":4.4768,"price_display":"4.48","price_state":"stated","total_value":58032.7584,"total_display":"58,032.76","total_whole":"58,033","shares_owned_after":723752.0,"shares_owned_after_display":"723,752","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-28","filed_date":"2022-02-01","scope":"insider","n_lines":2},{"id":6973372,"accession":"0000899243-22-003553","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-003553","line_url":"/filing/0000899243-22-003553#line-2","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16272.0,"shares_display":"16,272","price_per_share":4.8227,"price_display":"4.82","price_state":"stated","total_value":78474.9744,"total_display":"78,474.97","total_whole":"78,475","shares_owned_after":712294.0,"shares_owned_after_display":"712,294","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-27","filed_date":"2022-01-28","scope":"insider"},{"id":6973368,"accession":"0000899243-22-003553","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-003553","line_url":"/filing/0000899243-22-003553#line-1","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; Ledo Capital, LLC","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19528.0,"shares_display":"19,528","price_per_share":5.0074,"price_display":"5.01","price_state":"stated","total_value":97784.5072,"total_display":"97,784.51","total_whole":"97,785","shares_owned_after":696022.0,"shares_owned_after_display":"696,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-26","filed_date":"2022-01-28","scope":"insider"},{"id":6234682,"accession":"0000899243-22-001744","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-001744","line_url":"/filing/0000899243-22-001744","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Levy Noah G.; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Ledo Capital, LLC; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":91270.0,"shares_display":"91,270","price_per_share":3.9981,"price_display":"4.00","price_state":"stated","total_value":364906.587,"total_display":"364,906.59","total_whole":"364,907","shares_owned_after":987118.0,"shares_owned_after_display":"987,118","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-12","scope":"insider","n_lines":2},{"id":6234673,"accession":"0000899243-22-001744","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-001744","line_url":"/filing/0000899243-22-001744","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Levy Noah G.; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Ledo Capital, LLC; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14679.0,"shares_display":"14,679","price_per_share":3.8344,"price_display":"3.83","price_state":"stated","total_value":56285.1576,"total_display":"56,285.16","total_whole":"56,285","shares_owned_after":910576.0,"shares_owned_after_display":"910,576","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-12","scope":"insider","n_lines":2},{"id":6740324,"accession":"0000899243-22-001470","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-001470","line_url":"/filing/0000899243-22-001470","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Newtyn Management, LLC; Levy Noah G.; Ledo Capital, LLC; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN PARTNERS, LP","owner_display_name":"Newtyn Management, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8780.0,"shares_display":"8,780","price_per_share":3.8182,"price_display":"3.82","price_state":"stated","total_value":33523.796,"total_display":"33,523.80","total_whole":"33,524","shares_owned_after":901857.0,"shares_owned_after_display":"901,857","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-07","filed_date":"2022-01-10","scope":"insider","n_lines":2},{"id":4083618,"accession":"0000899243-21-001417","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-21-001417","line_url":"/filing/0000899243-21-001417#line-5","is_derivative":false,"issuer_cik":"0001548707","issuer_name":"Garrett Motion Inc.","issuer_ticker":"GTX","issuer_name_source":null,"issuer_url":"/issuer/0001548707","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":62846.0,"shares_display":"62,846","price_per_share":4.663,"price_display":"4.66","price_state":"stated","total_value":293050.898,"total_display":"293,050.90","total_whole":"293,051","shares_owned_after":1802095.0,"shares_owned_after_display":"1,802,095","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-11","scope":"insider"},{"id":4083616,"accession":"0000899243-21-001417","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-001417","line_url":"/filing/0000899243-21-001417#line-4","is_derivative":false,"issuer_cik":"0001548707","issuer_name":"Garrett Motion Inc.","issuer_ticker":"GTX","issuer_name_source":null,"issuer_url":"/issuer/0001548707","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16939.0,"shares_display":"16,939","price_per_share":4.734,"price_display":"4.73","price_state":"stated","total_value":80189.226,"total_display":"80,189.23","total_whole":"80,189","shares_owned_after":1739249.0,"shares_owned_after_display":"1,739,249","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-07","filed_date":"2021-01-11","scope":"insider"},{"id":4083613,"accession":"0000899243-21-001417","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-001417","line_url":"/filing/0000899243-21-001417#line-3","is_derivative":false,"issuer_cik":"0001548707","issuer_name":"Garrett Motion Inc.","issuer_ticker":"GTX","issuer_name_source":null,"issuer_url":"/issuer/0001548707","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":67310.0,"shares_display":"67,310","price_per_share":4.629,"price_display":"4.63","price_state":"stated","total_value":311577.99,"total_display":"311,577.99","total_whole":"311,578","shares_owned_after":1722310.0,"shares_owned_after_display":"1,722,310","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-06","filed_date":"2021-01-11","scope":"insider"},{"id":4083609,"accession":"0000899243-21-001417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-001417","line_url":"/filing/0000899243-21-001417#line-2","is_derivative":false,"issuer_cik":"0001548707","issuer_name":"Garrett Motion Inc.","issuer_ticker":"GTX","issuer_name_source":null,"issuer_url":"/issuer/0001548707","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60112.0,"shares_display":"60,112","price_per_share":4.399,"price_display":"4.40","price_state":"stated","total_value":264432.688,"total_display":"264,432.69","total_whole":"264,433","shares_owned_after":1655000.0,"shares_owned_after_display":"1,655,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-04","filed_date":"2021-01-11","scope":"insider"},{"id":4083605,"accession":"0000899243-21-001417","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-001417","line_url":"/filing/0000899243-21-001417#line-1","is_derivative":false,"issuer_cik":"0001548707","issuer_name":"Garrett Motion Inc.","issuer_ticker":"GTX","issuer_name_source":null,"issuer_url":"/issuer/0001548707","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60112.0,"shares_display":"60,112","price_per_share":4.402,"price_display":"4.40","price_state":"stated","total_value":264613.024,"total_display":"264,613.02","total_whole":"264,613","shares_owned_after":1715112.0,"shares_owned_after_display":"1,715,112","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-04","filed_date":"2021-01-11","scope":"insider"},{"id":3240102,"accession":"0000899243-20-032668","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-032668","line_url":"/filing/0000899243-20-032668","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; NEWTYN TE PARTNERS, LP; Newtyn Capital Partners, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":29776.0,"shares_display":"29,776","price_per_share":3.9991,"price_display":"4.00","price_state":"stated","total_value":119077.2016,"total_display":"119,077.20","total_whole":"119,077","shares_owned_after":896642.0,"shares_owned_after_display":"896,642","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-01","filed_date":"2020-12-03","scope":"insider","n_lines":2},{"id":2908142,"accession":"0000899243-20-032258","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-032258","line_url":"/filing/0000899243-20-032258","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; Newtyn Capital Partners, LP; NEWTYN PARTNERS, LP; Levy Noah G.; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":69087.0,"shares_display":"69,087","price_per_share":3.65,"price_display":"3.65","price_state":"stated","total_value":252167.55,"total_display":"252,167.55","total_whole":"252,168","shares_owned_after":879283.0,"shares_owned_after_display":"879,283","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-24","filed_date":"2020-11-27","scope":"insider","n_lines":2},{"id":3280284,"accession":"0000899243-20-031115","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-031115","line_url":"/filing/0000899243-20-031115","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP; Newtyn Management, LLC; Levy Noah G.","owner_display_name":"Ledo Capital, LLC","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":56490.0,"shares_display":"56,490","price_per_share":3.6451,"price_display":"3.65","price_state":"stated","total_value":205911.699,"total_display":"205,911.70","total_whole":"205,912","shares_owned_after":839005.0,"shares_owned_after_display":"839,005","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-12","filed_date":"2020-11-16","scope":"insider","n_lines":2},{"id":3033248,"accession":"0000899243-20-022561","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-022561","line_url":"/filing/0000899243-20-022561","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"NEWTYN TE PARTNERS, LP; NEWTYN PARTNERS, LP; Newtyn Capital Partners, LP; Newtyn Management, LLC; Levy Noah G.; Ledo Capital, LLC","owner_display_name":"NEWTYN TE PARTNERS, LP","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":608.0,"shares_display":"608","price_per_share":3.5,"price_display":"3.50","price_state":"stated","total_value":2128.0,"total_display":"2,128.00","total_whole":"2,128","shares_owned_after":806071.0,"shares_owned_after_display":"806,071","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-13","filed_date":"2020-08-17","scope":"insider","n_lines":2},{"id":2953328,"accession":"0000899243-20-022283","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-022283","line_url":"/filing/0000899243-20-022283","is_derivative":false,"issuer_cik":"0001274792","issuer_name":"MERRIMACK PHARMACEUTICALS INC","issuer_ticker":"MACK","issuer_name_source":null,"issuer_url":"/issuer/0001274792","owner_cik":null,"owner_name":"Levy Noah G.; Ledo Capital, LLC; NEWTYN PARTNERS, LP; Newtyn Management, LLC; Newtyn Capital Partners, LP; NEWTYN TE PARTNERS, LP","owner_display_name":"Levy Noah G.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":3.493,"price_display":"3.49","price_state":"stated","total_value":6986.0,"total_display":"6,986.00","total_whole":"6,986","shares_owned_after":805717.0,"shares_owned_after_display":"805,717","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-12","filed_date":"2020-08-13","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2020-08-12|2953324","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001274792","name":"MERRIMACK PHARMACEUTICALS INC","url":"/issuer/0001274792","role":"Director, Other","n_filings":23,"first_seen":"2020-04-07","last_seen":"2023-01-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001735707","name":"Garrett Motion Inc.","url":"/issuer/0001735707","role":"Other","n_filings":1,"first_seen":"2021-01-11","last_seen":"2021-01-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001788608","retrieved_at":"2026-08-23T08:23:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}